Skip to content
Tarlatamab

Tarlatamab

Regular price $920.00 USD
Sale price Regular price

THE SCIENCE, IN DETAIL

Know your product.

Specifications
Bioactivity
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.
Casnumber
2307488-83-9
Purity
>98.0%
Target synonyms
AMG-757
Technical documents

Documents

A PARTNER IN YOUR RESEARCH

More time for discovery. Less time sourcing.

Bring your laboratory requirements together with scientific advice, global sourcing and dedicated procurement support.

Explore our services

Starting a new laboratory?

Plan your laboratory with our New-Lab programme.

Discover New-Lab